Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 5/20 | 0.39 |
| ▸ | CTSD | P07339 | 4/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.38 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986990 | 0.92 | ANO1 (0.45) | SMN1; SMN2ALOX5APFEN1ANO1LMNA | |
| SCHEMBL270827 | 0.92 | ANO1 (0.45) | SMN1; SMN2ALOX5APFEN1ANO1LMNA | |
| SCHEMBL269653 | 0.91 | ANO1 (0.40) | SMN1; SMN2ALOX5APFEN1ANO1CAPN1 | |
| SCHEMBL268754 | 0.88 | ALOX5AP (0.39) | SMN1; SMN2ALOX5APFEN1ANO1CAPN1 | |
| SCHEMBL268078 | 0.85 | ANO1 (0.38) | SMN1; SMN2ALOX5APFEN1ANO1EIF2S1 | |
| SCHEMBL270520 | 0.85 | ALOX5AP (0.40) | SMN1; SMN2ALOX5APFEN1ANO1LMNA | |
| SCHEMBL269072 | 0.85 | ALOX5AP (0.40) | SMN1; SMN2ALOX5APFEN1ANO1LMNA | |
| SCHEMBL270158 | 0.85 | DPP4 (0.40) | SMN1; SMN2ALOX5APFEN1ANO1 | |
| SCHEMBL268660 | 0.85 | ANO1 (0.44) | SMN1; SMN2ANO1P2RX7CAPN1PRKCI | |
| SCHEMBL268387 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2ALOX5APFEN1ANO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | SMN1; SMN2 4330/4885BACE1 610/4885CTSD 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.